Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL969707 | 0.94 | CCR5 (0.43) | CCR5PTGS1PTGS2CYP1A2CYP3A4 | |
| SCHEMBL969062 | 0.81 | CCR5 (0.40) | CCR5 | |
| SCHEMBL971855 | 0.81 | CCR5 (0.40) | CCR5CYP3A4 | |
| SCHEMBL969048 | 0.80 | CCR5 (0.39) | CCR5 | |
| SCHEMBL968222 | 0.80 | CCR5 (0.39) | CCR5 | |
| SCHEMBL966962 | 0.78 | CYP3A4 (0.44) | CCR5PTGS1PTGS2CYP1A2CYP3A4 | |
| SCHEMBL968071 | 0.78 | CCR5 (0.40) | CCR5PTGS1PTGS2CYP1A2CYP3A4 | |
| SCHEMBL967375 | 0.77 | CCR5 (0.42) | CCR5 | |
| SCHEMBL969673 | 0.76 | CCR5 (0.36) | CCR5 | |
| SCHEMBL968657 | 0.76 | PDE9A (0.41) | CCR5PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875607-B2 | Neurodegenerative disorders; antiinflammatory agents; antiischemic agents; neuropathic pain; antiepileptic agents; Parkinson's disease; Alzheimer's disease; antidiabetic agents; 3-(6-Hydroxy-2-methyl-3,4,7,8,9,10-hexahydro-7,10-methano-2H -benzo[h]chromen-2-yl)-propionic acid methyl ester | AMPERE LIFE SCIENCES, INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-20090170814-A1 | 7,8-BICYCLOAKYL-CHROMAN DERIVATIVES | EDISON PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-7470798-B2 | Neurodegenerative disorders; antiinflammatory agents; strokes; antiischemic agents; neuropathic pain; brain disorders; antiepileptic agents; Parkinson's disease ; amyotropic lateral sclerosis; Alzheimer's disease; antidiabetic agents | EDISON PHARMACEUTICALS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| WO-2005033093-A1 | 7,8-BICYCLOALKYL-CHROMAN DERIVATIVES | GALILEO PHARMACEUTICALS, INC. (US) | 2005-04-14 | — | — | WO | disclosed |
| US-20050065149-A1 | Neurodegenerative disorders; antiinflammatory agents; strokes; antiischemic agents; neuropathic pain; brain disorders; antiepileptic agents; Parkinson's disease ; amyotropic lateral sclerosis; Alzheimer's disease; antidiabetic agents | PTC THERAPEUTICS, INC. | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065149-A1 | Neurodegenerative disorders; antiinflammatory agents; strokes; antiischemic agents; neuropathic pain; brain disorders; antiepileptic agents; Parkinson's disease ; amyotropic lateral sclerosis; Alzheimer's disease; antidiabetic agents | NLN, ACAA2, CS | CCR5 3955/4885PTGS1 352/4885PTGS2 856/4885 |
| US-20090170814-A1 | 7,8-BICYCLOAKYL-CHROMAN DERIVATIVES | COQ8A, TFAM, CS | CCR5 2287/4885PTGS1 1129/4885PTGS2 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.